Pharmacology

ranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complicationranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complication

ranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complicationranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complication

ranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complicationranolazine, dyspnea, chronic stable angina, dypsnea on exertion, DOE, dizziness, constipation, peripheral edema, cardiac complication

Listeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNFListeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNF

Listeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNFListeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNF

Listeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNFListeria, endocaritis, Infection, infliximab, Rheumatic Disease, anti-tumor necrosis factor alpfa, anti-TNF alpha, anti-TNF

carbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapycarbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapy

carbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapycarbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapy

carbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapycarbohydrates, glycemic control, insulin, hypoglycemia, insulin infusion therapy

analgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditoryanalgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditory

analgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditoryanalgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditory

analgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditoryanalgesics, hearing loss, aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, NSAIDs, auditory

estrogen, progestin, coronary artery disease, coronary heart disease, CAD, CHD, menopause, postmenopause, cardioprotective

estrogen, progestin, coronary artery disease, coronary heart disease, CAD, CHD, menopause, postmenopause, cardioprotective

estrogen, progestin, coronary artery disease, coronary heart disease, CAD, CHD, menopause, postmenopause, cardioprotective

epoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursionepoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursion

epoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursionepoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursion

epoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursionepoprostenol, acute pulmonary emoblism, vasodilator, vasoconstriction, right ventricular overload, systolic pulmonary artery pressure, right ventricular fractional area change, tricuspid annular plane systolic excursion

drug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirindrug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirin

drug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirindrug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirin

drug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirindrug-eluting stents, myocardial infarction, stent thrombosis, clopidogrel, cilostazol, aspirin

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia